Comparative Pharmacology
Head-to-head clinical analysis: EXTINA versus M ZOLE 3 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTINA versus M ZOLE 3 COMBINATION PACK.
EXTINA vs M-ZOLE 3 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
Miconazole inhibits fungal CYP450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity. Zinc pyrithione inhibits fungal growth by disrupting membrane transport and inhibiting energy metabolism.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
A single oral dose of 3 tablets (M-ZOLE 3 COMBINATION PACK) as a one-time treatment.
None Documented
None Documented
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Terminal elimination half-life 20-30 hours in healthy adults; prolonged in renal impairment (up to 40-50 hours) and hepatic impairment
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Renal: ~70-80% as unchanged drug and metabolites; biliary/fecal: ~20%
Category C
Category C
Antifungal
Antifungal